257 related articles for article (PubMed ID: 19378345)
21. Hepatitis B inactive carriers: clinical course and outcomes.
Tong MJ; Trieu J
J Dig Dis; 2013 Jun; 14(6):311-7. PubMed ID: 23433008
[TBL] [Abstract][Full Text] [Related]
22. [Hepatic steatosis: a common reason for elevated alanine aminotransferase levels in HBsAg-positive chronic hepatitis B patients with low HBV DNA loads].
Shi JP; Fan JG; Lou GQ; Zhang L; Hu CB; Wu R; Xun YH
Zhonghua Gan Zang Bing Za Zhi; 2008 Nov; 16(11):818-22. PubMed ID: 19032864
[TBL] [Abstract][Full Text] [Related]
23. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels.
Tsang PS; Trinh H; Garcia RT; Phan JT; Ha NB; Nguyen H; Nguyen K; Keeffe EB; Nguyen MH
Clin Gastroenterol Hepatol; 2008 May; 6(5):569-74. PubMed ID: 18455697
[TBL] [Abstract][Full Text] [Related]
24. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project).
Zacharakis GH; Koskinas J; Kotsiou S; Papoutselis M; Tzara F; Vafeiadis N; Archimandritis AJ; Papoutselis K
J Med Virol; 2005 Oct; 77(2):173-9. PubMed ID: 16121378
[TBL] [Abstract][Full Text] [Related]
25. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
26. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
Chien RN; Liaw YF
Antivir Ther; 2006; 11(7):947-52. PubMed ID: 17302259
[TBL] [Abstract][Full Text] [Related]
27. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
28. Long term follow-up of a large cohort of inactive HBsAg (+)/ HBeAg (-)/ anti-HBe (+) carriers in Greece.
Gigi E; Lalla T; Orphanou E; Sinakos E; Vrettou E; Raptopoulou-Gigi M
J Gastrointestin Liver Dis; 2007 Mar; 16(1):19-22. PubMed ID: 17410284
[TBL] [Abstract][Full Text] [Related]
29. Age as a predictor of significant fibrosis features in HBeAg-negative chronic hepatitis B virus infection with persistently normal alanine aminotransferase.
Tan Y; Ye Y; Zhou X; Chen L; Wen D
PLoS One; 2015; 10(4):e0123452. PubMed ID: 25885705
[TBL] [Abstract][Full Text] [Related]
30. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels.
Hu KQ; Schiff ER; Kowdley KV; Min AD; Shiffman ML; Lee WM; Goodman ZD; Dau LO; Peschell KJ; Fagan EA; Flaherty JF
J Clin Gastroenterol; 2010 Aug; 44(7):510-6. PubMed ID: 20179614
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients.
Chan HL; Hui Y; Leung NW; Ching JY; Chan FK; Sung JJ
Am J Gastroenterol; 2000 Dec; 95(12):3547-51. PubMed ID: 11151891
[TBL] [Abstract][Full Text] [Related]
32. The long-term course of chronic hepatitis B.
Di Marco V; Lo Iacono O; Cammà C; Vaccaro A; Giunta M; Martorana G; Fuschi P; Almasio PL; Craxì A
Hepatology; 1999 Jul; 30(1):257-64. PubMed ID: 10385664
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
Yuen MF; Hui CK; Cheng CC; Wu CH; Lai YP; Lai CL
Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
[TBL] [Abstract][Full Text] [Related]
34. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
[TBL] [Abstract][Full Text] [Related]
36. Markers of disease activity in chronic hepatitis B virus infection.
Yalcin K; Degertekin H; Yildiz F; Celik Y
Clin Invest Med; 2003 Feb; 26(1):27-34. PubMed ID: 12659467
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B.
Alam S; Ahmad N; Mustafa G; Shrestha A; Alam AK; Khan M
Liver Int; 2011 Jul; 31(6):824-30. PubMed ID: 21645213
[TBL] [Abstract][Full Text] [Related]
39. [Histological changes in the livers of chronic hepatitis B patients with persistently normal serum alanine transaminase levels].
Gui HL; Xie Q; Wang H; Cai W; Lin ZM; Jiang S; Xu P; Zhou XQ; Guo Q; Yu H
Zhonghua Gan Zang Bing Za Zhi; 2007 Dec; 15(12):881-5. PubMed ID: 18171518
[TBL] [Abstract][Full Text] [Related]
40. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
Reijnders JG; Rijckborst V; Sonneveld MJ; Scherbeijn SM; Boucher CA; Hansen BE; Janssen HL
J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
